Fig. 2: The four Proteomic subtypes show distinct clinical relevance. | British Journal of Cancer

Fig. 2: The four Proteomic subtypes show distinct clinical relevance.

From: Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets

Fig. 2

a The association of proteomic subtypes with 7 clinical variables. Kruskal-Wallis test was used for continuous variable CA125 (U/ml, the serum CA125 before debulking surgery or neoadjuvant chemotherapy). Fisher’s exact tests were used for other categorical variables (***p < 0.001, **p < 0.01, *p < 0.05). (Time of Surgery: PDS = primary debulking surgery, IDS = interval debulking surgery, refers to surgery after neoadjuvant chemotherapy (NACT)). b The distribution of samples with 4 Proteomic subtypes in different FIGO stages, metastasis, and tissue sites. c The distribution of samples with different platinum response in 4 Proteomic subtypes. d The distribution of serum CA125 level in 4 Proteomic subtypes. (Kruskal-Wallis test, **p < 0.01, *p < 0.05).

Back to article page